We use cookies to analyze site traffic and improve your experience.
By accepting, you consent to the use of analytics cookies.

TRGP:NYSETarga Resources, Inc. Analysis

Data as of 2026-06-26 - not real-time

$273.45

Latest Price

7/10Risk

Risk Level: Medium

Executive Summary

Targa Resources is trading at $273.45, comfortably above its 20‑day ($264.54) and 50‑day ($258.45) simple moving averages, indicating a sustained upward bias. The 30‑day volatility of roughly 29% and a beta of 0.71 suggest the stock moves more sharply than the broader market. Momentum gauges are mixed: the RSI sits at 59, just shy of overbought, while the MACD line remains bullish with a modest positive histogram. Technical support at $252.97 and resistance near $276.26 frame the near‑term price corridor, and current volume is on an increasing trend. Recent news shows the stock alternating between modest gains and small declines, yet it consistently outperforms peers on trading days. The fear‑and‑greed index reading of “Extreme Greed” reflects strong investor appetite despite the elevated volatility.
On the fundamentals side, TRGP posts a trailing PE of 27.9 versus an industry average of 20.2, signaling a premium valuation. A striking ROE of 74% is offset by a staggering debt‑to‑equity ratio above 580 and negative free cash flow, raising concerns about balance‑sheet resilience. The dividend yield of 1.55% is modest and the payout ratio of roughly 41% sits on thin cash cushions given the $100 M cash balance. A discounted cash‑flow model pins fair value near $72, implying the market price is significantly overvalued, while analyst consensus remains a “Buy” with a median target of $285. Given the modest upside of about 4.5% to the DCF estimate and the structural debt load, the stock appears more a growth‑oriented play than a value buy. Investors should therefore weigh the strong earnings trajectory against the sustainability of cash generation and dividend payments.

Market Outlook

Short Term

< 1 year
Neutral
Model confidence: 6/10

Key Factors

  • price near resistance
  • bullish momentum but limited upside
  • high volatility

Medium Term

1–3 years
Positive
Model confidence: 7/10

Key Factors

  • analyst target price above current
  • strong earnings growth
  • moderate debt servicing capacity

Long Term

> 3 years
Neutral
Model confidence: 5/10

Key Factors

  • excessive leverage
  • negative free cash flow
  • uncertain dividend sustainability

Key Metrics & Analysis

Financial Health

Revenue Growth-10.20%
Profit Margin12.87%
P/E Ratio27.9
ROE74.10%
ROA9.13%
Debt/Equity585.25
P/B Ratio19.1
Op. Cash Flow$3.7B
Free Cash Flow$-318550016
Industry P/E20.2

Technical Analysis

TrendBullish
RSI59.0
Support$252.97
Resistance$276.26
MA 20$264.54
MA 50$258.45
MA 200$209.01
MACDBullish
VolumeIncreasing
Fear & Greed Index87.7

Valuation

Fair Value$72.05
Target Price$285.71
Upside/Downside4.49%
GradeOvervalued
TypeGrowth
Dividend Yield1.55%

Risk Assessment

Beta0.02
Volatility29.25%
Sector RiskMedium
Reg. RiskMedium
Geo RiskLow
Currency RiskLow
Liquidity RiskMedium

This analysis may contain inaccuracies and is provided for informational and research purposes only. It is not personal investment advice, a recommendation, or an instruction to buy, sell, or hold any asset.